
Sonnet BioTherapeutics Holdings Investor Relations Material
Latest events

Q2 2025
13 May, 2025

Q1 2025
13 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Sonnet BioTherapeutics Holdings Inc
Access all reports
Sonnet BioTherapeutics Holdings Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development of innovative biologic drugs for cancer and other serious diseases. The company utilizes a proprietary platform to design fully human fusion proteins that enhance the therapeutic activity and delivery of cytokines. Sonnet’s pipeline targets various solid tumors and immunological conditions, with development efforts supported by preclinical and clinical research. The company is headquartered in Princeton, New Jersey, and its shares are listed on the NASDAQ.
Key slides for Sonnet BioTherapeutics Holdings Inc


Investor Presentation
Sonnet BioTherapeutics Holdings Inc


Investor Presentation
Sonnet BioTherapeutics Holdings Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
SONN
Country
🇺🇸 United States